首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1351102

2030 年基因治療市場預測：依部門市場和地區分類的全球分析

Gene Therapy Market Forecasts to 2030 - Global Analysis By Vector (Non-Viral Vectors & Viral Vectors), Gene Type (Antigen, Cytokine, Tumor Suppressor & Other Gene Types), Delivery Method (In Vivo & Ex Vivo), Application, End User & By Geography

出版日期: 2023年09月01日 | 出版商:

Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，2023 年全球基因治療市場規模為 88 億美元，預計預測期內年複合成長率為 20.6%，到 2030 年將達到 326.6 億美元。

人類基因療法是治療方法。他們的目的是為了治療目的而改變或調節活細胞的基因表現或生物特性。惰性無法正常運作的致病基因、用健康基因的副本取代致病基因、將新的或修飾的基因引入體內來治療疾病，這些都是基因治療的一些方法。正在研究使用基因療法的產品來治療癌症、遺傳性疾病和感染疾病疾病。

根據 ACS 的《2022 年癌症事實與數據》，2022 年美國將報告約 1,918,030 例新癌症病例和 609,360 例癌症死亡。目前多種基因治療策略被用於治療癌症。

新基因治療技術

借助基因療法，以前只能暫時治療的疾病現在可以永久治療。基因療法長期以來一直失敗，但近年來，已經報導了成功且長期的治療方法。對於多種遺傳疾病，包括血液異常、免疫力缺乏、視力障礙、神經細胞再生、代謝障礙和幾種癌症，已經取得了有希望的結果。基因療法有潛力成為一種個體化治療方法，可以更特異性治癒各種疾病，同時副作用更少。基因療法是將遺傳物質引入患者體內以治療疾病或至少改善臨床狀況，正在推動市場成長。

基因治療產品受到嚴格法規

在全球範圍內，基因療法的使用正在迅速擴大。這是因為高齡化，許多慢性疾病是可以透過早期發現和及時治療來避免的。同樣，參與企業必須遵守一系列法規，以獲得當局的許可在某個地區推出其產品。任何程序中最困難的課題之一就是遵守這些嚴格的限制。基因治療藥物在不同國家有不同程度的上市前核准。

神經系統和腫瘤疾病的比例增加

罕見的遺傳疾病在世界各地的人們中變得越來越常見。國家罕見疾病組織 (NORD) 估計，在美國，每年萬分之一的比例是由脊髓性肌肉萎縮症引起的。專業經歷了技術發展，使以前被認為無法治癒的疾病變得更容易治癒。另一方面，世界上最常見的疾病之一是癌症。這些基因療法有助於預防由於前幾代遺傳的基因突變而特別容易患某些癌症的人的疾病。

昂貴的治療費用

為了治療疾病，患者的基因組可能會被改變、刪除或添加，作為稱為基因治療的新醫療程序的一部分。儘管基因治療仍處於起步階段，但人們對治療甚至治癒先前的疑難雜症抱持著很大的期望。在許多國家，基因治療的費用在很大程度上仍然法規，是根據具體情況確定的，通常是拋棄式支付。

COVID-19 的影響：

COVID-19 對基因治療市場的整體影響仍然有利，因為前往醫院和診所接受基因治療 (ICI) 的癌症患者數量有所減少，導致對基因治療產品的需求減少。例如，NCBI預測，到2020年，美國癌症患者數量將減少約50%，在COVID-19期間，基因治療產品的市場需求也將減少約50%。

預計病毒載體部分在預測期內將是最大的

控制病毒載體表達治療基因的能力使其成為改變特定細胞類型和組織的最有效的基因轉移方法，因此預計病毒載體部門將享有良好的生長。目前正在研究幾種類型的病毒用於將基因引入細胞以進行臨時或永久基因改造表達的潛力。為了逃避受感染宿主的免疫監視，病毒已經進化到能夠有效地將核酸傳遞到有限的細胞類型。這些特性使病毒作為基因治療的基因轉移載體具有吸引力，並正在推動市場成長。

預計醫院領域在預測期內的年複合成長率最高。

預計醫院領域在預測期內的年複合成長率最高。這是因為這些設施中的治療方法高度可用且容易獲得，這有助於普及。預計該細分市場將在整個預測期內保持主導地位。隨著提供神經系統和癌症疾病最先進治療的獨立診所的興起，診所市場也有望擴大。

比最大的地區

就預測期內的核准數量和銷售額而言，預計北美將在預測期內佔據最大的市場佔有率，隨著更多大小公司投資研發以創造最佳藥物，該市場預計將成長。預計未來將繼續擴大治療範圍。政府投資水準的增加和某些疾病罹患率的上升也推動了市場的發展。脊髓性肌肉萎縮症基金會估計，到 2020 年，美國將有 10,000 至 25,000兒童和成人受到脊髓性肌肉萎縮症的罹患，使其成為一種相當普及。這是一種疾病。

複合年複合成長率最高的地區：

預計亞太地區在預測期內的年複合成長率最高。這是由於亞太地區人口眾多，醫療需求未被滿足，以及在管理罕見但穩定成長的疾病方面對突破性技術的需求日益成長。由於資源容易取得、當地大型公司的存在以及政府財政支持的增加，預計亞太地區基因治療商業應用市場將在預測期內顯著擴大。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

公司簡介
- 其他市場參與者的綜合分析（最多 3 家公司）
- 主要企業SWOT分析（最多3家企業）
區域分割
- 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
競爭基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲國家
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲

第11章進展

合約、夥伴關係、協作和合資企業
收購和合併
新產品發布
業務擴展
其他關鍵策略

第12章公司簡介

Amgen Inc.
Biogen Inc.
Bluebird Bio Inc.
Gilead Sciences Inc.
Novartis AG
F. Hoffmann-La Roche Ltd
UniQure NV
Abeona Therapeutics Inc.
Generation Bio
Poseida Therapeutics
Astellas Pharma
Voyager Therapeutics Inc.
Jazz Pharmaceuticals, Inc
GlaxoSmithKline plc
Spark Therapeutics Inc
Sarepta Therapeutics
Orchard Therapeutics
Shenzhen SiBiono GeneTech
Shanghai Sunway Biotech Co. Ltd.
CRISPR Therapeutics AG

簡介目錄圖表

Product Code: SMRC23789

According to Stratistics MRC, the Global Gene Therapy Market is accounted for $8.80 billion in 2023 and is expected to reach $32.66 billion by 2030 growing at a CAGR of 20.6% during the forecast period. Human gene therapy is a procedure that alters a person's genes to treat or cure disease. It aims to change or regulate a gene's expression or the biological characteristics of live cells for therapeutic purpose. Inactivating a disease-causing gene that is not working correctly, replacing a disease-causing gene with a healthy copy of the gene, and introducing a new or modified gene into the body to cure a disease are some of the ways that gene therapies can operate. Products utilizing gene therapy are being investigated for the treatment of diseases including cancer, genetic disorders, and infectious diseases.

According to the ACS 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 deaths due to cancers are estimated to be reported in the United States in 2022. In the treatment of cancer, various gene therapy strategies are currently employed.

Market Dynamics:

Driver:

Novel gene therapy techniques

Ailments that previously only received temporary therapies now have permanent remedies because to gene therapy. Gene therapy failed for a very long time; nevertheless, in recent years, successful and long-lasting treated instances have been documented. Promising results have been reached for a wide range of genetic ailments, including blood abnormalities, immunological inadequacies, eyesight problems, nerve cell regeneration, metabolic disorders, and several cancer kinds. Gene therapy has the potential to be a personalized treatment that can "cure" a range of diseases with more specificity and fewer negative effects. Gene therapy is the practice of transferring genetic material to a patient in order to treat a disease or, at the very least, improve their clinical state which enhances the growth of the market.

Restraint:

Gene therapy products are subject to strict restrictions

Globally, the use of gene therapy is expanding quickly because to the aging population and a number of chronic diseases that can be avoided with early detection and prompt treatment. Likewise, in order to receive clearance from higher authorities for the product's introduction in an area, gene therapy market participants must go by a set of rules. One of the most challenging duties among all the procedures is adhering to these strict restrictions. Different gene therapy medicines have different pre-market approval levels depending on the nation.

Opportunity:

Increasing rates of neurological and oncological disorders

Rare genetic illnesses are becoming more common among people all over the world. The National Organization for Rare Diseases (NORD) estimates that 1 in 10,000 live births in the United States occur each year due to spinal muscular atrophy. The profession has experienced technological developments that have made it easier to cure diseases that were formerly thought to be incurable. On the other hand, one of the most common diseases in the world is cancer. These gene treatments assist individuals who are especially susceptible to developing specific forms of cancer due to genetic mutations handed down from the previous generation in preventing the disease.

Threat:

High cost of treatment

In order to treat an illness, a patient's genome may be altered, deleted, or added to as part of a novel medical procedure known as gene therapy. Gene therapy has already demonstrated significant promise for the treatment and even cure of once-intractable disorders, despite the fact that it is still in its infancy. In many countries, the cost of gene therapy is still largely unregulated and decided on a case-by-case basis, typically focused on a single upfront payment.

COVID-19 Impact:

Due to a decrease in the number of cancer patients visiting hospitals and clinics for gene therapy (ICI), which resulted in a decrease in demand for gene therapy products, COVID-19's overall impact on the market for gene therapy remained unfavorable. For instance, the NCBI estimates that the number of cancer patients in the U.S. would drop by around 50% by 2020, and that the market's demand for gene therapy products will also drop by about 50% during COVID-19.

The viral vectors segment is expected to be the largest during the forecast period

The viral vectors segment is estimated to have a lucrative growth, due to the ability to control viral vectors to express therapeutic genes makes them the most efficient method of gene transfer for altering a particular cell type or tissue. Several virus types are being researched right now for their potential to be used to transfer genes to cells for either temporary or permanent transgenic expression. In order to circumvent immune monitoring by an infected host, viruses have evolved to become extremely effective at delivering nucleic acids to a limited range of cell types. These characteristics make viruses appealing gene delivery vectors for gene therapy, thus propelling the growth of the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, as the prevalence is caused by the treatment modalities' great availability and accessibility in such institutions. Throughout the projection period, it is expected that this market segment will continue to rule. Due to the rise of independent clinics offering cutting-edge treatments for neurological and cancer disorders, the clinics market is also expected to expand.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the number of approvals and the amount of money made throughout the projected period, and the market will continue to grow as more major and small businesses make R&D expenditures in the creation of medications for optimum therapy. The market is also being driven by the governments' expanding investment levels and the rising incidence of certain ailments. The Spinal Muscular Atrophy Foundation estimates that between 10,000 and 25,000 children and adults in the United States will have spinal muscular atrophy by the year 2020, making it a reasonably prevalent condition.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the country's sizable population's unmet medical demands and rising need for breakthrough technology in the management of uncommon but steadily escalating diseases. Due to the easy access to resources, the presence of big corporations locally, and rising government funding, the Asia Pacific market for the commercial use of genetic treatments is predicted to have considerable expansion over the projected period.

Key players in the market:

Some of the key players profiled in the Gene Therapy Market include: Amgen Inc. , Biogen Inc., Bluebird Bio Inc., Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche Ltd, UniQure NV, Abeona Therapeutics Inc., Generation Bio, Poseida Therapeutics, Astellas Pharma, Voyager Therapeutics Inc., Jazz Pharmaceuticals, Inc, GlaxoSmithKline plc, Spark Therapeutics Inc, Sarepta Therapeutics, Orchard Therapeutics, Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd. and CRISPR Therapeutics AG

Key Developments:

In August 2023, Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam.

In July 2023, Biogen to Acquire Reata Pharmaceuticals, Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.

In February 2023, Kite, a Gilead Company announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Vectors Covered:

Non-Viral Vectors
Viral Vectors

Gene Types Covered:

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Other Gene Types

Delivery Methods Covered:

In Vivo
Ex Vivo

Applications Covered:

DMD (Duchenne Muscular Dystrophy)
Neurological Diseases
Cancer
Hepatological Diseases
Rare Diseases
Oncological Disorders
Acute Lymphoblastic Leukemia (ALL)
Peripheral arterial disease
Other Applications

End Users Covered:

Cancer Institutes
Hospitals
Research Institutes
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Gene Therapy Market, By Vector

5.1 Introduction
5.2 Non-Viral Vectors
- 5.2.1 Oligonucleotides
- 5.2.2 Other Non-Viral Vectors
5.3 Viral Vectors
- 5.3.1 Retro Viral Vectors
- 5.3.2 Adeno-Associated Virus Vectors
- 5.3.3 Lentiviral Vector
- 5.3.4 Herpes Virus Vector
- 5.3.5 Other Viral Vectors

6 Global Gene Therapy Market, By Gene Type

6.1 Introduction
6.2 Antigen
6.3 Cytokine
6.4 Tumor Suppressor
6.5 Suicide
6.6 Deficiency
6.7 Growth factors
6.8 Receptors
6.9 Other Gene Types

7 Global Gene Therapy Market, By Delivery Method

7.1 Introduction
7.2 In Vivo
7.3 Ex Vivo

8 Global Gene Therapy Market, By Application

8.1 Introduction
8.2 DMD (Duchenne Muscular Dystrophy)
8.3 Neurological Diseases
8.4 Cancer
8.5 Hepatological Diseases
8.6 Rare Diseases
8.7 Oncological Disorders
8.8 Acute Lymphoblastic Leukemia (ALL)
8.9 Peripheral arterial disease
8.10 Other Applications

9 Global Gene Therapy Market, By End User

9.1 Introduction
9.2 Cancer Institutes
9.3 Hospitals
9.4 Research Institutes
9.5 Other End Users

10 Global Gene Therapy Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Amgen Inc.
12.2 Biogen Inc.
12.3 Bluebird Bio Inc.
12.4 Gilead Sciences Inc.
12.5 Novartis AG
12.6 F. Hoffmann-La Roche Ltd
12.7 UniQure NV
12.8 Abeona Therapeutics Inc.
12.9 Generation Bio
12.10 Poseida Therapeutics
12.11 Astellas Pharma
12.12 Voyager Therapeutics Inc.
12.12 Jazz Pharmaceuticals, Inc
12.14 GlaxoSmithKline plc
12.15 Spark Therapeutics Inc
12.16 Sarepta Therapeutics
12.17 Orchard Therapeutics
12.18 Shenzhen SiBiono GeneTech
12.19 Shanghai Sunway Biotech Co. Ltd.
12.20 CRISPR Therapeutics AG

簡介目錄圖表

List of Tables

Table 1 Global Gene Therapy Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Gene Therapy Market Outlook, By Vector (2021-2030) ($MN)
Table 3 Global Gene Therapy Market Outlook, By Non-Viral Vectors (2021-2030) ($MN)
Table 4 Global Gene Therapy Market Outlook, By Oligonucleotides (2021-2030) ($MN)
Table 5 Global Gene Therapy Market Outlook, By Other Non-Viral Vectors (2021-2030) ($MN)
Table 6 Global Gene Therapy Market Outlook, By Viral Vectors (2021-2030) ($MN)
Table 7 Global Gene Therapy Market Outlook, By Retro Viral Vectors (2021-2030) ($MN)
Table 8 Global Gene Therapy Market Outlook, By Adeno-Associated Virus Vectors (2021-2030) ($MN)
Table 9 Global Gene Therapy Market Outlook, By Lentiviral Vector (2021-2030) ($MN)
Table 10 Global Gene Therapy Market Outlook, By Herpes Virus Vector (2021-2030) ($MN)
Table 11 Global Gene Therapy Market Outlook, By Other Viral Vectors (2021-2030) ($MN)
Table 12 Global Gene Therapy Market Outlook, By Gene Type (2021-2030) ($MN)
Table 13 Global Gene Therapy Market Outlook, By Antigen (2021-2030) ($MN)
Table 14 Global Gene Therapy Market Outlook, By Cytokine (2021-2030) ($MN)
Table 15 Global Gene Therapy Market Outlook, By Tumor Suppressor (2021-2030) ($MN)
Table 16 Global Gene Therapy Market Outlook, By Suicide (2021-2030) ($MN)
Table 17 Global Gene Therapy Market Outlook, By Deficiency (2021-2030) ($MN)
Table 18 Global Gene Therapy Market Outlook, By Growth factors (2021-2030) ($MN)
Table 19 Global Gene Therapy Market Outlook, By Receptors (2021-2030) ($MN)
Table 20 Global Gene Therapy Market Outlook, By Other Gene Types (2021-2030) ($MN)
Table 21 Global Gene Therapy Market Outlook, By Delivery Method (2021-2030) ($MN)
Table 22 Global Gene Therapy Market Outlook, By In Vivo (2021-2030) ($MN)
Table 23 Global Gene Therapy Market Outlook, By Ex Vivo (2021-2030) ($MN)
Table 24 Global Gene Therapy Market Outlook, By Application (2021-2030) ($MN)
Table 25 Global Gene Therapy Market Outlook, By DMD (Duchenne Muscular Dystrophy) (2021-2030) ($MN)
Table 26 Global Gene Therapy Market Outlook, By Neurological Diseases (2021-2030) ($MN)
Table 27 Global Gene Therapy Market Outlook, By Cancer (2021-2030) ($MN)
Table 28 Global Gene Therapy Market Outlook, By Hepatological Diseases (2021-2030) ($MN)
Table 29 Global Gene Therapy Market Outlook, By Rare Diseases (2021-2030) ($MN)
Table 30 Global Gene Therapy Market Outlook, By Oncological Disorders (2021-2030) ($MN)
Table 31 Global Gene Therapy Market Outlook, By Acute Lymphoblastic Leukemia (ALL) (2021-2030) ($MN)
Table 32 Global Gene Therapy Market Outlook, By Peripheral arterial disease (2021-2030) ($MN)
Table 33 Global Gene Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
Table 34 Global Gene Therapy Market Outlook, By End User (2021-2030) ($MN)
Table 35 Global Gene Therapy Market Outlook, By Cancer Institutes (2021-2030) ($MN)
Table 36 Global Gene Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
Table 37 Global Gene Therapy Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 38 Global Gene Therapy Market Outlook, By Other End Users (2021-2030) ($MN)